Company Profile · Healthcare

Sunshine Guojian Pharmaceutical Shanghai Co Ltd

688336 · Shanghai

Country: China
Employees: 1,023
Website: 3s-guojian.com

Buffett Score

45/100

Weak

Financial snapshot

Market capCN¥37.13B

Revenue (TTM)CN¥4.42B

EBITDACN¥3.43B

Profit margin69.65%

ROE43.53%

P/E (TTM)12.08

Forward P/E0

EPSCN¥3.43

Dividend yield0.87%

52-week rangeCN¥33.93 – CN¥65.85

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

About the company

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include Enbrel, a recombinant human type II tumor necrosis factor receptor-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation; and Enbrel, an anti-IL-17A humanized monoclonal antibody ambroxol injection for the treatment of moderate to severe plaque psoriasis. The company was founded in 2002 and is based in Shanghai, China.

Background

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.

Research on this stock

No reports on this stock in your language yet.